10:59 AM EDT, 08/05/2025 (MT Newswires) -- European equities traded in the US as American depositary receipts were lower late Tuesday morning, declining 0.19% to 1,453.18 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies ( DBVT ) and accommodations booking company trivago (TRVG), which climbed 9.5% and 6.3% respectively. They were followed by brewing company Anheuser-Busch InBev ( BUD ) and biopharmaceutical company Genfit ( GNFT ) , which rose 2.6% and 1.9% respectively.

The decliners from continental Europe were led by biopharmaceutical company Cellectis ( CLLS ) and semiconductor company Sequans Communications ( SQNS ) , which fell 12% and 5.8% respectively. They were followed by pharmaceutical company Novo Nordisk ( NVO ) and biotech firm Evaxion ( EVAX ) , which were down 2.5% and 1.8% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Adaptimmune Therapeutics ( ADAP ) and medical device maker Smith & Nephew ( SNN ) , which surged 38% and 14% respectively. They were followed by alcoholic beverage company Diageo ( DEO ) and Trinity Biotech ( TRIB ) , which increased 3.5% and 2.7% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana ( NCNA ) and Akari Therapeutics ( AKTX ) , which dropped 7.2% and 5.3% respectively. They were followed by technology services and consulting firm Endava ( DAVA ) and financial services company Lloyds Banking Group ( LYG ) , which lost 1.6% and 1.5% respectively.